Shenzhen Kangtai Biological Products Co., Ltd. is a high-risk pharmaceutical company in China. Specializing in human vaccine research and development, they produce a variety of vaccines such as recombinant hepatitis B vaccine and measles-rubella combined live attenuated vaccine. With an ESG score of 30.3, Shenzhen Kangtai Biological Products Co., Ltd. focuses on sustainability and governance in their operations.